Trifluridine/tipiracil plus bevacizumab (FTD/TPI plus BEV) and trifluridine/tipiracil (FTD/TPI) monotherapy in metastatic colorectal cancer (mCRC): Results of a meta-analysis.

被引：0
|
作者：
Yoshino, Takayuki
Taieb, Julien
Andre, Thierry
Kuboki, Yasutoshi
Pfeiffer, Per
Kumar, Amit
Hochster, Howard S.
机构：
[1] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Japan
[2] Paris Descartes Univ, Hop Europ een Georges Pompidou, Paris, France
[3] Hop St Antoine, Paris, France
[4] Natl Canc Ctr Hosp East, Kashiwa, Japan
[5] Odense Univ Hosp, Odense, Denmark
[6] SmartAnalyst India Pvt Ltd, Gurugram, Haryan, India
[7] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3568
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study
    Li, Rong-Rong
    Zhou, Hui-Jun
    Zeng, De-Yu
    Jiang, Shao-Feng
    Liu, Wu
    Fruehling, Petter
    Liu, Zhen-Yang
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (02) : 612 - 629
  • [32] Trifluridine/tipiracil (FTD/TPI) in extensively pre-treated metastatic colorectal cancer (mCRC) patients: Evaluation of prognostic subgroups of the TALLISUR study
    Karthaus, Meinolf
    Weiss, Lena
    Riera-Knorrenschild, Jorge
    Kretzschmar, Albrecht
    Welslau, Manfred
    Vehling-Kaiser, Ursula
    Pelz, Henning
    Ettrich, Thomas Jens
    Held, Swantje
    Kehrmann, Linde
    Hess, Juergen
    Reislaender, Timo
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] Relationship between fluoropyrimidine (FPD) exposure and outcomes in patients with metastatic colorectal cancer (mCRC) receiving trifluridine/tipiracil (FTD/TPI) with or without bevacizumab (BEV) in the phase 3 SUNLIGHT trial.
    Fakih, Marwan
    Prager, Gerald W.
    Taieb, Julien
    Calleja, Elizabeth Martine
    Liu, Mei
    Amellal, Nadia
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 114 - 114
  • [34] Trifluridine-tipiracil plus bevacizumab in refractory metastatic colorectal cancer
    Tasseau, Clara
    Gallois, Claire
    BULLETIN DU CANCER, 2024, 111 (12) : 1087 - 1088
  • [35] Real-world adherence and treatment discontinuation with trifluridine/tipiracil (FTD-TPI) compared with regorafenib (REG) for the treatment of metastatic colorectal cancer (mCRC).
    Patel, Anuj K.
    Duh, Mei Sheng
    Barghout, Victoria E.
    Yenikomshian, Mihran Ara
    Xiao, Yongling
    Wynant, Willy
    Tabesh, Majid
    Fuchs, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] G-CSF secondary prophylaxis in patients (pts) with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD/TPI): The GERCOR LONGBOARD study
    Bachet, J-B.
    Bouche, O.
    Trouilloud, I.
    Larnicol, M. L. Garcia
    Vernerey, D.
    Boisson, C.
    Hautefeuille, V.
    Laly, M.
    Rinaldi, Y.
    Fenioux, C.
    Smith, D.
    Desrame, J.
    Lecaille, C.
    Chibaudel, B.
    Wagner, J-P.
    Texereau, P.
    Vienot, A.
    Tougeron, D.
    Borg, C.
    ANNALS OF ONCOLOGY, 2024, 35 : S447 - S447
  • [37] JFMC51-1702-C7: Phase II study investigating efficacy and safety of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) in patients (pts) with metastatic colorectal cancer (mCRC) refractory or intolerant to standard chemotherapies
    Kazama, K.
    Nakamura, M.
    Tanaka, R.
    Ojima, H.
    Makiyama, A.
    Matsuhashi, N.
    Kagawa, Y.
    Okuda, H.
    Asayama, M.
    Yuasa, Y.
    Negoro, Y.
    Mushiake, H.
    Manaka, D.
    Oba, K.
    Yoshino, T.
    Yoshida, K.
    Maehara, Y.
    Yamazaki, K.
    Oki, E.
    Takahashi, T.
    ANNALS OF ONCOLOGY, 2019, 30 : 234 - 234
  • [38] Trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastroesophageal junction cancer (mGEJC): Subgroup analysis from TAGS.
    Mansoor, Wasat
    Arkenau, Hendrik-Tobias
    Alsina, Maria
    Shitara, Kohei
    Tejani, Mohamedtaki Abdulaziz
    Thuss-Patience, Peter C.
    Cuffe, Sinead
    Dvorkin, Mikhail
    Park, David
    Ando, Takayuki
    Van Den Eynde, Marc
    Beretta, Giordano D.
    Zaniboni, Alberto
    Doi, Toshihiko
    Tabernero, Josep
    Ilson, David H.
    Makris, Lukas
    McGuigan, Sandra
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [39] Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase IIIb PRECONNECT study
    Taieb, J.
    Falcone, A.
    Lonardi, S.
    Price, T. J.
    Bachet, J-B.
    Wyrwicz, L.
    Ciardiello, F.
    Becquart, M.
    Mounedji, N.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2018, 29 : 155 - 155
  • [40] Survival impact on regorafenib (REG) and trifluridine/tipiracil hydrochloride (FTD/TPI) for patients with metastatic colorectal cancer: Single institutional experience.
    Chida, Keigo
    Kotani, Daisuke
    Sawada, Kentaro
    Nakamura, Yoshiaki
    Kawazoe, Akihito
    Kuboki, Yasutoshi
    Shitara, Kohei
    Kojima, Takashi
    Taniguchi, Hiroya
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345